Scientists develop revolutionary eye drops to treat age-related blindness

May 15, 2017, University of Birmingham
Credit: CC0 Public Domain

Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.

The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as (AMD).

AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.

A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.

This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.

Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham's Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.

The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.

Dr de Cogan said: "The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.

"Efficacious self-administered drug application by eye would lead to a significant reduction in adverse outcomes and compared with current treatments.

"The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.

"We believe this is going to be very important in terms of empowering of patients and reducing the cost of to the NHS."

Explore further: Experimental drug shows promise for sight-stealing eye condition

More information: Felicity de Cogan et al, Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides, Investigative Opthalmology & Visual Science (2017). DOI: 10.1167/iovs.16-20072

Related Stories

Experimental drug shows promise for sight-stealing eye condition

January 19, 2017
An experimental drug may one day make treatment simpler for patients suffering from vision-threatening age-related macular degeneration, researchers say.

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma

March 16, 2017
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

Global experts discuss new approaches and innovations in ocular drug delivery systems

November 7, 2016
The estimated number of visually impaired people in the world is 285 million, with 39 million blind people. About 65 percent of visually impaired people and 82 percent of all blind people are 50 years or older. Four major ...

Gene therapy in a droplet could treat eye diseases, prevent blindness

July 27, 2016
Eye diseases such as diabetic retinopathy and age-related macular degeneration are among the leading causes of irreversible vision loss and blindness worldwide. Currently, gene therapy can be administered to treat these conditions—but ...

New hepatitis C treatments more effective, tolerable: FDA

May 11, 2017
(HealthDay)—Hepatitis C can be cured in about three months, allowing people with the viral disease to live longer, healthier lives, the U.S. Food and Drug Administration (FDA) says.

Recommended for you

FDA approves contact lenses that shade the sun

April 13, 2018
The lives of contact lens wearers just got a whole lot easier.

New glaucoma treatment could ease symptoms while you sleep

April 11, 2018
Eye drops developed by UBC researchers could one day treat glaucoma while you sleep - helping to heal a condition that is one of the leading causes of blindness around the world.

Researchers test stem cell-based retinal implant for common cause of vision loss

April 4, 2018
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell-based retinal implant is feasible for use in people with advanced dry age-related ...

Post-Ebola cataract surgery can safely restore vision

April 4, 2018
Cataract surgery can be safely performed on Ebola virus disease survivors with impaired vision, Emory Eye Center ophthalmologists and 40 colleagues around the world report.

Older adults with small social networks less likely to get cataract surgery

March 9, 2018
Close family relationships and a strong social network may help older adults see the world better—literally.

A retinal implant that is more effective against blindness

March 9, 2018
EPFL researchers have developed a new type of retinal implant for people who have become blind due to the loss of photoreceptor cells in their retinas. The implant partially restores their visual field and can significantly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.